A Study Comparing Different Dosing Regimens of Ixekizumab (LY2439821) in Participants With Moderate to Severe Plaque Psoriasis (IXORA-P)

I1F-MC-RHBP -

The main purpose of this study is to evaluate the efficacy of ixekizumab dosing regimens in participants with plaque psoriasis.

Trial Summary

Age Range
≥18 years
Conditions the trial is for
Plaque Psoriasis
What the trial is testing?
Ixekizumab
Could I receive a Placebo?
Yes
Enrollment Goal
1257
Trial Dates
Aug 1, 2015 - Aug 3, 2017
How long will I be in the trial?
Your participation could last up to 80 weeks and include approximately 18 visits to the study center.
Trial Phase
III

Lilly Trial Alerts

Not the right fit? Sign up to receive updates about new trials that are listed or when a new trial site begins enrolling near you.